Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

13
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
13
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

19
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
19
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

25
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
25
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

22
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
22
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

37
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
37
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

24
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
24

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Paclitaxel-Coated Balloon Versus Uncoated Balloon for Coronary In-Stent Restenosis: Two-Year Follow-Up of the AGENT-IDE Randomized Clinical Trial.

Circulation·2026
Same author

Lessons Learned from the Feasibility Phase of the REvascularization CHoices Among Under-Represented Groups Evaluation (RECHARGE) Trial Program.

American heart journal·2026
Same author

Revascularization in Acute Myocardial Infarction and Cardiogenic Shock in the Era of Mechanical Circulatory Support.

Interventional cardiology clinics·2026
Same author

Unmasking the Threat: Acute Hepatitis E Virus Infection in a Liver Transplant Recipient.

Case reports in transplantation·2026
Same author

Oxygenation-sensitive cardiovascular magnetic resonance imaging to identify coronary microvascular and vasomotor dysfunction in angina and no obstructive coronary artery disease.

European heart journal. Cardiovascular Imaging·2026
Same author

Enhancing invasive coronary function testing: Multivessel assessment of coronary microvascular dysfunction in patients with angina and no obstructive coronary artery disease (ANOCA).

American heart journal·2026

Related Experiment Video

Updated: Aug 19, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.3K

Mechanical Circulatory Support in Patients With COVID-19 Presenting With Myocardial Infarction.

Raviteja R Guddeti1, Cristina Sanina2, Rajiv Jauhar3

  • 1Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital, Minneapolis, Minnesota.

The American Journal of Cardiology
|December 2, 2022
PubMed
Summary

Patients with ST-segment elevation myocardial infarction (STEMI) and COVID-19 requiring mechanical circulatory support (MCS) face significantly higher in-hospital mortality. This increased risk is likely due to greater pulmonary complications in COVID-19 patients needing MCS.

More Related Videos

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.7K
The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

21.8K

Related Experiment Videos

Last Updated: Aug 19, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.3K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.7K
The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

21.8K

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Critical Care Medicine

Background:

  • ST-segment elevation myocardial infarction (STEMI) complicated by COVID-19 is linked to increased risks of cardiogenic shock and mortality.
  • The utilization and clinical impact of mechanical circulatory support (MCS) in these patients remain under-investigated.

Purpose of the Study:

  • To investigate patterns of MCS use, patient demographics, and outcomes in individuals with COVID-19 and STEMI.
  • To compare these findings with a control group of patients with STEMI who tested negative for COVID-19.

Main Methods:

  • Analysis of data from the North American COVID-19 Myocardial Infarction (NACMI) registry, a prospective observational study.
  • Inclusion of 1,379 patients (586 COVID-19 positive, 793 COVID-19 negative) from January 2020 to November 2021.
  • Comparison of baseline characteristics and in-hospital outcomes between COVID-19 positive and negative patients who received MCS.

Main Results:

  • Overall MCS use was 12.3%, with similar rates in both COVID-19 positive (12.1%) and negative (12.4%) groups.
  • Intra-aortic balloon pump was the most common MCS device in both groups.
  • The primary composite outcome was significantly higher in COVID-19 positive patients requiring MCS (60% vs. 30%, p=0.001), driven by substantially higher in-hospital mortality (59% vs. 28%, p=0.001).

Conclusions:

  • COVID-19 positive patients with STEMI who require MCS exhibit exceptionally high in-hospital mortality rates.
  • Elevated pulmonary involvement in COVID-19 patients may contribute to the poorer outcomes observed in those requiring MCS.